论文部分内容阅读
本文探讨鼠神经因子治疗抗癌药希罗达致手足征(HFS)疗效的临床观察,并与维生素B6治疗HFS的疗效作对照。得出结论:HFS的发生与希罗达剂量积累有关,与年龄及既往是否曾使用过5-fu无关。口服希罗达同时配合NGF使用,明显减少HFS的发生,同时缓解HFS症状,从而避免希罗达使用者药物减量及停药,保证患者疗程、疗效。
This article discusses the clinical observation of the effect of murine neuro-factor on the treatment of HFS caused by anti-cancer drug Xeloda, and compares it with the therapeutic effect of vitamin B6 on HFS. Conclusions: The incidence of HFS is related to the dose accumulation of Xeloda and has nothing to do with the age and past 5-FU. Oral Xiloda with NGF at the same time, significantly reduce the occurrence of HFS, while alleviating HFS symptoms, thereby avoiding Xeloda users drug reduction and withdrawal, to ensure patient treatment, efficacy.